X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Manufacturing

Envirotainer Welcomes Delta Cargo as the latest airline to approve the new Releye RLP container

Content Team by Content Team
17th January 2022
in Manufacturing, Packaging & Logistic, Press Statements
Envirotainer launches the Releye RLP – simpler than passive, even better than active

Envirotainer, the global market leader in secure cold chain solutions for air transportation of pharmaceuticals, today announced that Delta Cargo has approved the Envirotainer Releye® RLP for usage on their fleet of aircrafts.

With this approval, Delta Cargo can now transport the Releye® RLP on their wide-reaching global network, increasing the capacity to meet the ever-growing need for temperature-controlled, high-quality, connected ULD solutions.

The Releye provides outstanding environmental performance, delivering up to 90% reduction in CO2 emissions compared to available passive solutions, based on life-cycle analysis. The Releye® RLP uses rechargeable batteries to power its electric heating and compressor cooling system and can power its system for over 170 hours on a single charge. With its unique feature set, the Releye® RLP sets a new standard for secure cold chain solutions bringing a temperature-controlled air freight container to market with a new footprint, industry-leading autonomy and fully integrated live monitoring.

“The introduction of the Releye® RLP, in combination with our CEIV certified pharma network, provides our customers with more choice when looking for reliable container options to support the growing demand for pharma and vaccine shipments” said Jannie Davel, Managing Director Cargo Commercial at Delta Cargo.

“We are happy to welcome Delta Cargo as a carrier of the Envirotainer Releye® RLP container,” says Don Harrison, Head of Global Key Accounts, Airlines at Envirotainer. He continued, “With the new Releye® RLP, Delta Cargo can offer their customers the latest active fully connected solution to protect the integrity and quality of air freight medicine products throughout the supply chain.”

About Envirotainer AB

Envirotainer is the global market leader in secure cold chain solutions for the pharmaceutical supply chain. The company develops, manufactures, and offers leasing of innovative container solutions, including validation, support, and service, for pharma products that require a controlled environment. Thanks to a truly global presence with the world’s active container fleet, the largest network, and an extensive industry expertise, Envirotainer is? able to meet the customers’ need for innovative and reliable solutions – available from any location to any destination. The company operates through an open, global network of airlines and forwarders and the headquarters is located outside of Stockholm, Sweden. For more information, please visit www.envirotainer.com.

 

Previous Post

LJI and Charles River Laboratories to collaborate on COVID-19 research

Next Post

Tevogen Bio Further Strengthens IP Portfolio With Additional Patent for Method of Preparing Its Investigational SARS-CoV-2 Specific T cell Therapy

Related Posts

Avadel Pharmaceuticals Receives
Drug Development

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

9th June 2025
Regulatory Trends in Pharma
Insights

Regulatory Trends in Pharma Manufacturing to Watch in 2025

29th May 2025
Pharmaceutical-Chemicals Market Booms with Rising API Demand
Asia

Pharmaceutical Chemicals Market Booms with Rising API Demand

28th May 2025
Drugmakers Asked to Strictly Follow the US Pricing Reforms
Manufacturing

Drugmakers Asked to Strictly Follow the US Pricing Reforms

28th May 2025
ACHEMA
Middle East and South Asia

ACHEMA Middle East to Debut in Riyadh in 2026 Trade Show

9th May 2025
Press Statements

APM Steam Highlights Comprehensive HVAC Insulation Services for Biopharmaceutical and Pharmaceutical Facilities

19th April 2025
Next Post
DCGI nod to Serum-Oxford covid-19 vaccine for phase 2, 3 clinical trials in India

Tevogen Bio Further Strengthens IP Portfolio With Additional Patent for Method of Preparing Its Investigational SARS-CoV-2 Specific T cell Therapy

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In